Position in VRTX
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$492,259
+$49,738 QoQ
Shares Held
991
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.16%
of 13F equity value
Holder Rank
#1,084
of 1,735 holders
Holding Since
Sep 2022
16 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in VRTX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Alta Advisers Ltd holds $746,039 across 2 Biotechnology names. VRTX ranks #1 (66.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
This page
|
991 | $492,259 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
407 | $253,780 |
All Filings in VRTX
Export CSV
16 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $492,259 | 991 | Shares | Defined | 2026-08-12 | |
| 2026-03-31 | $442,521 | 991 | Shares | Defined | 2026-05-07 | |
| 2025-12-31 | $449,279 | 991 | Shares | Defined | 2026-02-09 | |
| 2025-09-30 | $497,774 | 1,271 | Shares | Defined | 2025-10-31 | |
| 2025-06-30 | $565,849 | 1,271 | Shares | Defined | 2025-07-25 | |
| 2025-03-31 | $616,206 | 1,271 | Shares | Defined | 2025-04-25 | |
| 2024-12-31 | $350,751 | 871 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $325,556 | 700 | Shares | Defined | 2024-11-08 | |
| 2024-06-30 | $328,104 | 700 | Shares | Defined | 2024-08-08 | |
| 2024-03-31 | $292,607 | 700 | Shares | Defined | 2024-04-24 | |
| 2023-12-31 | $284,823 | 700 | Shares | Defined | 2024-02-12 | |
| 2023-09-30 | $243,418 | 700 | Shares | Defined | 2023-11-03 | |
| 2023-06-30 | $246,337 | 700 | Shares | Defined | 2023-07-25 | |
| 2023-03-31 | $220,549 | 700 | Shares | Defined | 2023-05-09 | |
| 2022-12-31 | $202,146 | 700 | Shares | Sole | 2023-01-27 | |
| 2022-09-30 | $202,678 | 700 | Shares | Sole | 2022-10-28 | |
| No filing history on record for this holder in this stock. | ||||||